Navigation Links
Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007

HAIFA, Israel, November 20 /PRNewswire-FirstCall/ --

- Third quarter Consolidated Net Income NIS 178 Million, Compared to NIS 24 Million Last Year; Third Quarter 2006 Results Adversely Affected by Northern Hostilities

- Company Publishing Today Hebrew Draft Prospectus for the Issue of Debentures Primarily for the Financing of the Strategic Plan; Debentures Were Rated AA Stable by Maalot, a Standard and Poor's Affiliation

Oil Refineries Ltd. (TASE: ORL) ("Oil Refineries" or the "Company") announced today its financial results for three and nine-month periods ending September 30, 2007.

The reported results for the third quarter and nine months 2007 exclude the results of Ashdod Refineries, which was sold at the end of the third quarter 2006, and which generated a substantial capital gain in the said third quarter. The results for the comparable period, the third quarter and nine months of 2006, are pro-forma figures and refer to the consolidated pro-forma statements.

Third Quarter Highlights

- Refining margin USD/bbl 5.7, compared to USD/bbl 7.3 in the third quarter 2006

- Company refining margin 52% higher than Mediterranean Ural Cracking Margin average of USD/bbl 3.75

- Consolidated EBITDA totaled NIS 326, compared to NIS 144 million in third quarter 2006

- Consolidated net income totaled NIS 178 million, compared to 24 million in third quarter 2006

- Quarterly results positively affected by the changes in the USD against the Israeli Shekel; Last year's third quarter results were negatively affected by the northern hostilities

Third Quarter Results

Refining margin for the third quarter totaled USD/bbl 5.7 (USD/MT 41.6), compared to the third quarter Mediterranean Ural Cracking Margin(i) average of USD/bbl 3.75(i) (USD/MT 27.4). Refining margin for the third quarter 2006 totaled USD/bbl 7.3 (USD/MT 52.9).

Consolidated EBITDA for the third quarter 2007 reached NIS 326 million, compare

SOURCE Oil Refineries Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:10/7/2015)... Calif. , Oct. 7, 2015  ChromaDex ... wellness and nutritional ingredients that creates science-based solutions ... sports nutrition, and pharmaceutical products, today announced that ... , CEO and Founder, is now available for ...   -->   ...
(Date:10/7/2015)... , Oct. 7, 2015  October is National Liver ... has committed to donating a portion of its October ... and hepatology practices. ... in a variety of ways; whether it is by ... world, collaborating with researchers in different disease and investigation ...
(Date:10/7/2015)... ... October 07, 2015 , ... Park Systems , ... Coatings to provide a comprehensive overview of the innovations in smart coatings using ... . This webinar will be given by Professor Roberto Advincula, professor with ...
(Date:10/7/2015)... ... October 07, 2015 , ... Tunnell Consulting , Inc. ... the Operational and Process Improvement practice. He brings to his role more than ... “I am delighted that Dr. Matzmorr is joining our team,” said Dr. Philippe Cini, ...
Breaking Biology Technology:
... Following the,establishment of their Industrial Management Board, ... is happy to announce its,official launch event to ... of M.B.N Nanomaterialia, the board members Mr Manfred ... Andrea Reinhardt of microTEC,look forward to a very ...
... Fame Coach Jim Calhoun Credits Early Diagnosis with ... two of AdvaMed 2007:,The MedTech Conference will highlight how ... technology as well as speakers on the,diversity and strength ... conference runs Oct. 1 through Oct. 3., Co-writing ...
... October 2 - Management and Distinguished ... Development Programs, as Well as on,the microRNA Field ... a global leader in,microRNA-based diagnostics and therapeutics, announced ... and their significant potential in cancer,treatment and other ...
Cached Biology Technology:
(Date:9/30/2015)... GARDENS, Fla. , Sept. 30, 2015  The ... this month issued another key ruling in favor of ... determination that Korean fingerprint scanner company Suprema and its ... Act of 1930, a trade provision that declares it ... import trade, by infringing two of Crossmatch,s patents, the ...
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
(Date:9/24/2015)...  EyeLock LLC, a market leader of iris-based identity ... latest technology in Booth #602 at next week,s ASIS ... EyeLock,s iris authentication technology provides an unprecedented level ... it the most proven way to authenticate one,s identity ... deliver a fast and friendly user experience to identify ...
Breaking Biology News(10 mins):
... tissues into mice, researchers report in the November Cell ... normal and obese mice. The findings suggest that the hormone ... insulin resistance and type 2 diabetes. , Insulin resistance, in ... sugar (glucose) levels, is a precursor to diabetes. ...
... Cancer Symposium features the latest findings in laboratory, translational ... on new and promising therapeutic approaches, as well as ... To help you take the best advantage of ... you to visit to view the ...
... N.Y. (Mon., Nov. 3, 2008) Understanding the ... tissues requires experimental systems that allow for the study ... laboratory. This month,s issue of Cold Spring ... with detailed instructions for setting up these experimental culture ...
Cached Biology News:
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Arginine vasopressin receptor (AVP-V2), rat. The peptide used for immunization has no significant similarity with AVP V1a or V1b receptors....
Biology Products: